| | Webinar: Removing Antibody Drug Discovery's DNA Bottleneck Tuesday, September 14 | 2pm ET / 11am PT GPCRs have proven to be one of the most challenging targets for antibody drug development. In this webinar, we describe the use of next-generation DNA synthesis tools to overcome the DNA bottleneck in antibody-based GPCR drug discovery. Learn More. |
Novartis scraps kidney transplant trial after control beats study drug Lilly's COVID-19 antibody combo cleared for nationwide use as feds say it can tackle the dominant delta variant Hospitals ramp up hiring, benefits offerings to counter the workforce shortage, survey says AstraZeneca strikes COVID-19 vaccine delivery deal with Europe, ending high-profile legal battle Cassava CEO, ‘dazed and confused’, takes to biotech defense handbook by blaming short sellers for woes CDC: 'Perfect storm' fueled a spike in healthcare-associated infections in 2020 A mini-CRISPR system could be 'Swiss knife' in gene editing MedPAC considers one-time funding boosts for Medicare in 2023 due to COVID-19 confusion COVID-19 tracker: EU probes rare safety concerns for Pfizer, J&J shots Florida Blue parent GuideWell to acquire Puerto Rico-based Triple-S Management Featured Story | By Nick Paul Taylor Novartis’ kidney transplant trial has crashed and burned. Having moved into phase 2 on the strength of evidence that iscalimab may prolong the durability of transplanted kidneys, Novartis has stopped the study after an interim analysis found it may be worse than standard of care. read more |
| |
|---|
|
Top Stories By Eric Sagonowsky Only a few days after Eli Lilly's COVID-19 antibody combo of bamlanivimab and etesevimab made its return in more than 20 states, federal officials are resuming distribution nationwide. In a Thursday alert, officials said Lilly's drug "can be used in all U.S. states, territories, and jurisdictions" based on data about variants circulating nationwide. read more By Dave Muoio A spring poll of 150 health systems outlined a stark contrast to last year, when lockdown-induced cost cutting spurred furloughs, layoffs and suspended benefits. read more By Noah Higgins-Dunn AstraZeneca and the European Commission have settled their months-long dispute over the company's planned shipments of millions of COVID-19 doses to EU countries. Under the agreement, AZ will supply the EU with 200 million jabs of its vaccine, known as Vaxzevria, by March 2022. read more By Ben Adams The Cassava saga continues as its chief Remi Barbier has come out, guns blazing, against accusations that the biotech may have deliberately misdirected investors on its recent Alzheimer’s readout. read more By Dave Muoio Between the heavy use of catheters and ventilators and industry-wide shortages of staff and supplies, the COVID-19 pandemic reversed years of progress in reducing preventable hospital infections, according to a new CDC analysis of national surveillance data. read more By Kyle LaHucik Researchers at Stanford University say they have created a mini version of the CRISPR-Cas system that could be easier to deliver into cells for gene therapies. The mini gene-editing system comes after CRISPR pioneer Intellia revealed first-in-human gene editing data in June. read more By Robert King The Medicare Payment Advisory Commission is considering implementing a one-time funding boost for providers in 2023 as the pandemic has made it difficult to discern long-term funding trends. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner The European Union's drug regulator is reviewing Pfizer and Johnson & Johnson's COVID-19 vaccines for potentially new, rare safety risks. Federal officials say Eli Lilly's antibody cocktail can now be used across the country. Plus more headlines. read more By Paige Minemyer The parties expect that the acquisition will close in the first half of 2022, pending regulatory approval. read more |
